Purpose
The purpose of this study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
Full Title
A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination with Second-line Therapy in Patients with Locally Advanced Unresectable, Recurrent and/ or Metastatic Hepatocellular Carcinoma
ClinicalTrials.Gov ID
NCT05733598
To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.